Want to see HK:3320 full AI Analyst Report?
Top Page
China Resources Pharmaceutical Group Ltd.
(3320)
Select Model
Select Model
Rating:68Neutral
Price Target:
HK$5.50
▲(19.31% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by attractive valuation (low P/E and strong dividend yield). Financial performance is stable with solid cash flow, but very thin net margins and a rising leverage trend materially temper the outlook. Technicals are mildly supportive, adding a modest positive tilt.
Positive Factors
Integrated business model
Vertical integration across distribution, retail and manufacturing creates durable revenue diversification and supply‑chain control. This reduces dependence on a single channel, enables cross‑selling and inventory efficiency, supporting stable cash flow and resilience over months.
Negative Factors
Very thin net margins
Net margins near 1–1.5% leave little room for error: small cost increases or pricing pressure materially reduce profits. Limited bottom‑line leverage constrains retained earnings, weakens return sensitivity, and hampers long‑term capacity to build equity organically.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated business model
Vertical integration across distribution, retail and manufacturing creates durable revenue diversification and supply‑chain control. This reduces dependence on a single channel, enables cross‑selling and inventory efficiency, supporting stable cash flow and resilience over months.
Read all positive factors
China Resources Pharmaceutical Group Ltd. (3320) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$28.21B
Dividend Yield5.36%
Average Volume (3M)7.86M
Price to Earnings (P/E)6.0
Beta (1Y)0.80
Revenue Growth7.94%
EPS Growth52.83%
CountryHK
Employees84,000
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,282,510,300
10 Day Avg. Volume10,750,072
30 Day Avg. Volume7,864,236
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)0.49
Price to Sales (P/S)0.09
P/FCF Ratio1.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$6.54Price Target Upside41.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
China Resources Pharmaceutical Group Ltd. Business Overview & Revenue Model
Company Description
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segme...
How the Company Makes Money
The company primarily makes money through (1) pharmaceutical distribution: selling medicines and healthcare products to hospitals, clinics, and other healthcare institutions, generating revenue based on the value and volume of products distributed...
China Resources Pharmaceutical Group Ltd. Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
52
Neutral
Cash Flow
70
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 300.01B | 274.18B | 270.40B | 223.13B | 193.24B |
| Gross Profit | 49.53B | 43.30B | 42.43B | 34.36B | 28.87B |
| EBITDA | 17.70B | 15.45B | 15.43B | 13.59B | 9.75B |
| Net Income | 4.50B | 3.57B | 4.24B | 3.64B | 3.08B |
Balance Sheet | |||||
| Total Assets | 318.34B | 274.28B | 271.48B | 214.19B | 202.83B |
| Cash, Cash Equivalents and Short-Term Investments | 31.05B | 27.28B | 35.46B | 28.56B | 30.45B |
| Total Debt | 104.87B | 73.43B | 62.16B | 56.06B | 55.45B |
| Total Liabilities | 187.52B | 169.90B | 169.20B | 134.14B | 125.57B |
| Stockholders Equity | 57.26B | 51.34B | 50.60B | 43.52B | 41.60B |
Cash Flow | |||||
| Free Cash Flow | 18.83B | 14.55B | 12.42B | 6.62B | 6.79B |
| Operating Cash Flow | 22.78B | 17.55B | 15.55B | 9.57B | 9.16B |
| Investing Cash Flow | -11.20B | -9.45B | -2.07B | -2.90B | -7.21B |
| Financing Cash Flow | -12.19B | -17.91B | -4.07B | -7.90B | 4.34B |
China Resources Pharmaceutical Group Ltd. Technical Analysis
Negative
4.61
Price Trends
4.68
Negative
4.79
Negative
4.72
Negative
Market Momentum
-0.09
Positive
38.03
Neutral
22.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3320, the sentiment is Negative. The current price of 4.61 is below the 20-day moving average (MA) of 4.66, below the 50-day MA of 4.68, and below the 200-day MA of 4.72, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 38.03 is Neutral, neither overbought nor oversold. The STOCH value of 22.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3320.
China Resources Pharmaceutical Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$16.67B | 26.04 | 3.09% | 3.53% | -12.86% | -83.10% | |
68 Neutral | HK$28.21B | 5.95 | 7.92% | 5.36% | 7.94% | 52.83% | |
67 Neutral | HK$25.01B | 14.47 | 11.97% | 7.74% | -5.90% | -18.84% | |
61 Neutral | HK$26.93B | 15.42 | 8.60% | 3.08% | 14.80% | -2.88% | |
59 Neutral | HK$36.34B | 12.78 | 6.64% | 6.34% | 6.58% | -4.29% | |
59 Neutral | HK$65.80B | 17.53 | 6.97% | 2.60% | 9.88% | 9.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3320
China Resources Pharmaceutical Group Ltd.
4.47
-0.26
-5.52%
HK:3933
The United Laboratories International Holdings
8.47
-7.91
-48.31%
HK:0867
China Medical System Holdings
11.18
-2.77
-19.86%
HK:0874
Guangzhou Baiyunshan Pharmaceutical Holdings Company
13.61
-3.90
-22.28%
HK:1513
Livzon Pharmaceutical Group
21.24
-13.29
-38.49%
HK:2196
Shanghai Fosun Pharmaceutical (Group) Co
17.29
-9.07
-34.41%
China Resources Pharmaceutical Group Ltd. Corporate Events
China Resources Pharmaceutical Moves to Become Largest Shareholder in Lier Chemical
Jul 29, 2026
China Resources Pharmaceutical Group Ltd., a Hong Kong-listed player in the pharmaceutical and healthcare products sector, is expanding its reach through its subsidiary CR Double-Crane. The subsidiary acts as a strategic investment arm, targeting ...
China Resources Pharmaceutical Raises RMB1 Billion in Second Tranche of 2026 Medium-Term Notes
Jul 29, 2026
China Resources Pharmaceutical Group Limited has announced that its wholly owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has completed the issuance of the second tranche of its 2026 medium-term notes in mainland China....
China Resources Pharmaceutical Raises RMB1 Billion via Medium-Term Notes in Mainland China
Jul 22, 2026
China Resources Pharmaceutical Group has completed the issuance of the first tranche of its 2026 medium term notes in the mainland China market via its wholly-owned unit China Resources Pharmaceutical Holdings. The notes carry a principal amount o...
China Resources Pharma Leads Bid for Strategic Stake in Lier Chemical
Jul 15, 2026
China Resources Pharmaceutical Group has disclosed that its indirect subsidiary China Resources Double-Crane Pharmaceutical ranked first in a public bidding process to acquire a 23.50% stake in Lier Chemical, a Shenzhen-listed producer of high-eff...
Tasly Delivers Profit Growth on Flat Revenue, Bolstering China Resources Pharmaceutical
Jul 14, 2026
China Resources Pharmaceutical Group has disclosed key unaudited interim figures from its subsidiary Tasly Pharmaceutical for the six months to 30 June 2026, highlighting the performance of one of its core assets in the mainland market. Tasly, lis...
CR Sanjiu’s First-Half 2026 Profit Declines Despite Revenue Growth
Jul 14, 2026
China Resources Sanjiu Medical Pharmaceutical Co., Ltd., a key subsidiary of China Resources Pharmaceutical Group Limited, reported unaudited preliminary financial results for the six months ended 30 June 2026. The Shenzhen-listed pharmaceutical ...
China Resources’ KPC Warns of Steep First‑Half Loss Amid Policy and Market Pressures
Jul 14, 2026
KPC Pharmaceuticals, a Shanghai‑listed subsidiary of China Resources Pharmaceutical Group, reported a sharp deterioration in earnings for the six months to 30 June 2026, with an unaudited net loss of RMB330 million to RMB400 million expected...
China Resources Pharmaceutical Refreshes Board With New Non-Executive Director
Jul 13, 2026
China Resources Pharmaceutical Group Ltd., a Hong Kong-incorporated and Hong Kong-listed pharmaceutical enterprise, runs extensive operations across China’s healthcare sector, from drug manufacturing to distribution and related medical servi...
China Resources Pharmaceutical Details Board and Committee Structure
Jul 13, 2026
China Resources Pharmaceutical Group Limited has disclosed the current composition of its board of directors, detailing the roles of its chairman, president, executive, non-executive, and independent non-executive directors. The announcement also ...
China Resources Pharmaceutical Raises RMB2 Billion in Third Tranche of 2026 PRC Bonds
Jun 26, 2026
China Resources Pharmaceutical Group Limited has announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group, has completed the public issuance of the third tranche of its 2026 corporate bonds in mainland China....
China Resources Pharmaceutical Wins Shareholder Backing for Dividend, Board and Capital Mandates
Jun 12, 2026
China Resources Pharmaceutical Group’s shareholders approved all resolutions at the 12 June 2026 annual general meeting, including adoption of the 2025 financial statements and a final dividend of RMB0.122 per share. Investors also backed th...
China Resources Pharmaceutical Wins Approval to Register Up to RMB5 Billion in Medium-Term Notes
May 29, 2026
China Resources Pharmaceutical Group said its wholly owned unit, China Resources Pharmaceutical Holdings, has obtained registration approval from China’s National Association of Financial Market Institutional Investors to issue up to RMB5 bi...
China Resources Pharmaceutical Sets Final 2025 Dividend Timetable
May 18, 2026
China Resources Pharmaceutical Group Limited has declared a final ordinary dividend of RMB 0.122 per share for the financial year ended 31 December 2025, with shareholders able to receive it in either Hong Kong dollars or renminbi. The default pay...
China Resources Pharmaceutical Sets AGM to Approve Dividend, Board Mandates and Share Buy-Back
May 18, 2026
China Resources Pharmaceutical Group Ltd. has called its annual general meeting for 12 June 2026 in Hong Kong to review the audited financial statements for the year ended 31 December 2025 and to seek shareholder approval for key corporate matters...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.